NLRP3 and metabolic dysfunction-associated steatohepatitis: Previous studies have shown that CPT can reduce the activation of caspase-1 activity and the secretion of IL-1β in mouse models of NLRP3 inflammasome-mediated diseases such as endotoxemia syndrome and nonalcoholic steatohepatitis (NASH) [6].